Myriad Genetics, Inc. (MYGN)

Check out top investors' recommendation for MYGN
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
48.40
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
80%/20%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Its molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual’s risk for developing disease later in life; determine a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy to ensure optimal dosing and reduced drug toxicity. The company offers various molecular diagnostic tests that include BRACAnalysis predictive medicine test for hereditary breast and ovarian cancer; COLARIS medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; and MELARIS medicine test for hereditary melanoma. It also provides OnDose, a personalized medicine test that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. In addition, the company, through its subsidiary, Myriad RBM, Inc., offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
William Quirk Piper Jaffray Buy   Oct 10, '18     53.00  Oct 10, '19  N/A 
Steve Beuchaw Morgan Stanley Buy   Oct 10, '18     54.00  Oct 10, '19  N/A 
Steve Beuchaw Morgan Stanley Buy   Aug 22, '18     49.00  Aug 22, '19  N/A 
Drew Jones Stephens Inc. Buy   Aug 22, '18     52.00  Aug 22, '19  N/A 
Derik De Bruin BofA Merrill Lynch Sell   Aug 22, '18     34.00  Aug 22, '19  N/A 
Sung Ji Nam Cantor Fitzgerald Buy   May 29, '18     42.00  May 29, '19  N/A 
Sung Ji Nam Cantor Fitzgerald Buy   Jan 16, '18     41.00  Jan 16, '19  N/A 
Drew Jones Stephens Inc. Buy   Jan 02, '18     45.00  Jan 02, '19  N/A 
Tycho Peterson JPMorgan Sell   Nov 10, '17     19.00  Nov 10, '18  N/A 
Tycho Peterson JPMorgan Sell   Jun 29, '17     16.00  Jun 29, '18  N/A 
Scott Gleason Stephens Inc. Buy   Mar 13, '17       Mar 13, '18  N/A 
Dan Leonard Leerink Swann Llc Sell   Jan 18, '17     15.00  Jan 18, '18  N/A 
Kevin Degeeter Ladenburg Thalmann & Co. Sell   Oct 10, '16       Oct 10, '17  N/A 
Derik De Bruin BofA Merrill Lynch Sell   Oct 10, '16       Oct 10, '17  N/A 
Scott Gleason Stephens Inc. Buy   Aug 11, '16     30.00  Aug 11, '17  N/A 
Derik De Bruin BofA Merrill Lynch Sell   Jul 29, '16       Jul 29, '17  N/A 
Drew Jones Stephens Inc. Buy   Nov 19, '15   44.19  47.00  Nov 19, '16  -61.98% 
William Quirk Piper Jaffray Buy   Nov 04, '15   46.16  47.00  Nov 04, '16  -64.77% 
Scott Gleason Stephens Inc. Buy   Sep 16, '15   41.30  47.00  Sep 16, '16  -45.98% 
William Quirk Piper Jaffray Buy   Sep 15, '15   40.75  45.00  Sep 15, '16  10.43% 
< previous12